NCT02304367 - Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 24, 2015

Primary Completion Date

July 27, 2017

Study Completion Date

January 21, 2021

Conditions

Tumor Induced Osteomalacia (TIO)Epidermal Nevus Syndrome (ENS)

Interventions

BIOLOGICAL

Burosumab

Solution for subcutaneous injection

Trial Locations (7)

Johns Hopkins University, Baltimore

Duke University, Durham

Indiana University Hospital, Indianapolis

Mayo Clinic, Rochester

Houston Methodist Research Institute, Houston

Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden

Yale University School of Medicine, New Haven